124 related articles for article (PubMed ID: 20144681)
41. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
42. Potential role of novel hepatocellular carcinoma-associated gene IDD01 in promoting tumorigenesis of HepG2 cell line.
Chen XY; Li JS; Ma J; Duan FL; Zhong P
Chin Med J (Engl); 2006 Oct; 119(20):1709-14. PubMed ID: 17097018
[TBL] [Abstract][Full Text] [Related]
43. [Epigallocatechin-3-gallate induces apoptosis in human hepatocellular carcinoma cells].
Chen XL; Wang Q; Cao LQ; Huang XH; Fu XH; Tan HX; Zhen MC; Chen JS
Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(36):2524-8. PubMed ID: 19080641
[TBL] [Abstract][Full Text] [Related]
44. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma.
Ikeguchi M; Hirooka Y; Kaibara N
Cancer; 2002 Nov; 95(9):1938-45. PubMed ID: 12404288
[TBL] [Abstract][Full Text] [Related]
45. Bystin-like protein is upregulated in hepatocellular carcinoma and required for nucleologenesis in cancer cell proliferation.
Wang H; Xiao W; Zhou Q; Chen Y; Yang S; Sheng J; Yin Y; Fan J; Zhou J
Cell Res; 2009 Oct; 19(10):1150-64. PubMed ID: 19687802
[TBL] [Abstract][Full Text] [Related]
46. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Gramantieri L; Giovannini C; Veronese A; Ferracin M; Sabbioni S; Calin GA; Grazi GL; Croce CM; Tavolari S; Chieco P; Negrini M; Bolondi L
Cancer Res; 2009 Jul; 69(14):5761-7. PubMed ID: 19584283
[TBL] [Abstract][Full Text] [Related]
47. [Experimental research of therapeutic effect on hepatocellular carcinoma of targeting SMYD3 gene inhibition by RNA interference].
Xu JY; Chen LB; Xu JY; Yang Z; Xu RH; Wei HY
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):481-4. PubMed ID: 16772086
[TBL] [Abstract][Full Text] [Related]
48. Role of constitutively activated and insulin-like growth factor-stimulated ERK1/2 signaling in human hepatoma cell proliferation and apoptosis: evidence for heterogeneity of tumor cell lines.
Alexia C; Lasfer M; Groyer A
Ann N Y Acad Sci; 2004 Dec; 1030():219-29. PubMed ID: 15659801
[TBL] [Abstract][Full Text] [Related]
49. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
50. Small interfering RNA-mediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection.
Walker T; Nolte A; Steger V; Makowiecki C; Mustafi M; Friedel G; Schlensak C; Wendel HP
Eur J Cardiothorac Surg; 2013 Mar; 43(3):628-33; discussion 633-4. PubMed ID: 23152437
[TBL] [Abstract][Full Text] [Related]
51. Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
Bae JS; Noh SJ; Kim KM; Jang KY; Chung MJ; Kim DG; Moon WS
Int J Oncol; 2014 Jan; 44(1):129-36. PubMed ID: 24173109
[TBL] [Abstract][Full Text] [Related]
52. All-trans retinoic acid protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating collagen 8A2.
Wang W; Xu G; Ding CL; Zhao LJ; Zhao P; Ren H; Qi ZT
FEBS J; 2013 Mar; 280(5):1308-19. PubMed ID: 23298258
[TBL] [Abstract][Full Text] [Related]
53. Characterization of E2F3a function in HepG2 liver cancer cells.
Li W; Ni GX; Zhang P; Zhang ZX; Li W; Wu Q
J Cell Biochem; 2010 Dec; 111(5):1244-51. PubMed ID: 20803551
[TBL] [Abstract][Full Text] [Related]
54. STAT1 negatively regulates hepatocellular carcinoma cell proliferation.
Chen G; Wang H; Xie S; Ma J; Wang G
Oncol Rep; 2013 Jun; 29(6):2303-10. PubMed ID: 23588992
[TBL] [Abstract][Full Text] [Related]
55. In vivo silencing of Reptin blocks the progression of human hepatocellular carcinoma in xenografts and is associated with replicative senescence.
Ménard L; Taras D; Grigoletto A; Haurie V; Nicou A; Dugot-Senant N; Costet P; Rousseau B; Rosenbaum J
J Hepatol; 2010 May; 52(5):681-9. PubMed ID: 20346530
[TBL] [Abstract][Full Text] [Related]
56. Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells.
Farra R; Dapas B; Baiz D; Tonon F; Chiaretti S; Del Sal G; Rustighi A; Elvassore N; Pozzato G; Grassi M; Grassi G
Biochimie; 2015 May; 112():85-95. PubMed ID: 25742740
[TBL] [Abstract][Full Text] [Related]
57. Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects.
Scaggiante B; Farra R; Dapas B; Baj G; Pozzato G; Grassi M; Zanconati F; Grassi G
Int J Pharm; 2016 Jun; 506(1-2):268-79. PubMed ID: 27094354
[TBL] [Abstract][Full Text] [Related]
58. Reduced expression of myocardin and serum response factor in the cavernous tissue of diabetic rats.
He SH; Wei AY; Yang Y; Hu YW; Luo XG; Liu Y; Zhang T
Andrologia; 2012 May; 44 Suppl 1():518-22. PubMed ID: 21950552
[TBL] [Abstract][Full Text] [Related]
59. [Effect of siRNA-mediated silencing of Notch2 on proliferation of the HepG2 human hepatocellular carcinoma cells].
Li J; Ding S; Ying L; Hu A; Hu Y; Liang X
Zhonghua Gan Zang Bing Za Zhi; 2014 May; 22(5):354-7. PubMed ID: 25180870
[TBL] [Abstract][Full Text] [Related]
60. Expression of serum response factor in gastric carcinoma and its molecular mechanisms involved in the regulation of the invasion and migration of SGC-7901 cells.
Zhao M; Xu H; He X; Hua H; Luo Y; Zuo L
Cancer Biother Radiopharm; 2013 Mar; 28(2):146-52. PubMed ID: 23134219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
